A federal judge has refused to dismiss a trio of antitrust lawsuits against pharmaceuticals giant GlaxoSmithKline that accuse the company of using a series of illegal tactics to delay the approval of generic versions of Flonase, a popular allergy drug.
Lawyers for GSK argued that all of its conduct is immune from antitrust liability under the Noerr-Pennington doctrine, but U.S. District Judge Anita B. Brody found that the plaintiffs may be able to prove that the conduct was nothing but a "sham" that enjoys no such immunity.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]